AstraZeneca has a target of $5 billion or more in peak annual sales for both Enhertu and Datroway as it pitches at its 2030 revenue target.

Daiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form of tumour affecting joints and tendons. TGCT – which is also ...